ClearPoint Neuro, Inc. — FY 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; comparisons are with FY 2020. This is an annual report, not a standalone fourth-quarter filing. ClearPoint develops and sells minimally invasive brain-surgery navigation devices and supports pharmaceutical and biotech partners developing brain drug and gene delivery therapies.
Financial results
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Revenue | $16.3 million | $12.8 million |
| Gross profit / margin | $11.3 million / 69% | $9.1 million / 71% |
| Operating loss | $13.4 million | $6.2 million |
| Net loss | $14.4 million | $6.8 million |
| Net loss per share, basic and diluted | $0.69 | $0.43 |
| Cash used in operating activities | $12.7 million | $7.8 million |
| Cash and cash equivalents at year-end | $54.1 million | $20.1 million |
Product revenue was $11.9 million, up 35%; service and other revenue was $4.4 million, up 10%. Functional neurosurgery navigation and therapy revenue rose 30% to $8.1 million; biologics and drug delivery revenue rose 31% to $6.8 million; capital equipment and software revenue was approximately $1.4 million, essentially unchanged.
Research and development expense increased 92% to $9.0 million; sales and marketing expense increased 29% to $6.9 million; general and administrative expense increased 66% to $8.8 million. Gross margin declined two percentage points, primarily due to higher allocated overhead. No EBITDA figure is provided in the supplied filing text.
At December 31, 2021, total assets were $65.6 million and total liabilities were $16.8 million. Current assets were $61.9 million versus current liabilities of $4.8 million. Secured convertible notes had a $10.0 million principal balance, due in 2025, and were secured by company assets. The company reported $48.8 million in stockholders’ equity. Cash flow from financing was $46.9 million, primarily reflecting the public share offering.
Changes and notable items
- Revenue increased 27%, supported by resumed elective procedures and increased activity among drug-delivery partners. ClearPoint system cases increased 36% to 929; active surgery centers remained approximately 60.
- Net loss more than doubled as operating expenses rose substantially, including investment in product development, staffing, and commercial expansion.
- Cash from operations used increased from $7.8 million to $12.7 million. The company raised approximately $46.8 million net in a February 2021 public offering and converted $15.0 million of note principal, plus accrued interest, into common shares during 2021.
- Cash and cash equivalents included approximately $48.4 million held in bank balances above FDIC-insured limits.
- A related-party customer that is also a stockholder and noteholder accounted for 18% of FY 2021 total revenue and 43% of biologics and drug-delivery revenue. The filing reports quarterly service fees of $0.7 million under the customer agreement.
Outlook, risks, and contingencies
Management anticipated increased revenue over the following 12 months from greater use at existing sites, new ClearPoint installations, and pharmaceutical-partner product sales and consulting. It also expected higher operating expenses, lower operating losses and cash usage, but stated that cash would likely continue to be consumed. Management believed year-end cash was sufficient for at least 12 months; it did not provide a specific revenue or earnings forecast in the supplied text.
- COVID-19 and future variants could again delay elective surgeries and partner clinical trials; supply-chain disruption, labor shortages, and inflation also pose risks.
- Growth depends on broader hospital adoption, successful expansion into operating rooms, and development and regulatory clearance of new products. Drug-delivery growth also depends on partners’ clinical-trial and regulatory outcomes.
- Customer concentration, reimbursement uncertainty, competition, reliance on single-source suppliers, and manufacturing at a single California facility could affect sales and supply.
- The company has incurred losses since inception, with an accumulated deficit of approximately $133.9 million. It warned that additional financing may be needed if plans or cash projections are not achieved, potentially diluting shareholders.
- The filing estimates a potential $7 billion brain drug-delivery market; this is a company estimate, and access depends on clinical and regulatory success.
- No material pending legal proceedings were reported. The independent auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; auditor attestation of internal control was not included.
Important facts for investors to verify
- Whether procedure volumes, new installations, and operating-room adoption continue to grow, and whether that growth improves gross margin and reduces cash burn.
- Revenue quality and concentration: contribution from the largest hospital customers and the related-party pharmaceutical customer, including the terms and continuity of its service agreement.
- Cash runway and financing needs relative to the $12.7 million FY 2021 operating cash outflow, planned spending, and the $10.0 million secured note due in 2025.
- Regulatory milestones, trial progress, and commercial outcomes for SmartFlow-related therapies and products under development; distinguish cleared uses from investigational uses.
- Exposure to COVID-related procedure delays, supplier disruptions, and the single-site manufacturing and above-insured bank-deposit risks.